Abbott announces the upcoming launch of NeuroSphere myPath, a digital health app designed to track and report on patient-perceived pain relief and general well-being associated with spinal cord stimulation (SCS) or dorsal root ganglion (DRG) therapy.
During the device trial period required before the permanent implant, the app allows patients to record their outcomes on pain and well-being while trialing their neurostimulation therapy.
This new digital health app will allow patients eligible for SCS or DRG therapy to use their Apple mobile device to connect with Abbott support, access educational resources and track the progress of their trial pain relief journey, according to Abbott in a media release.
“The COVID-19 pandemic put a spotlight on the need for digital and remote health tools. Patients will be able to see information on their phone that would typically only be accessible in a doctor’s office – helping patients to share their journey with their doctors.”
— Keith Boettiger, vice president, Neuromodulation, Abbott
Prior to committing to full implantation of a neuromodulation device, patients undergo a trial period to test device capabilities and capacity for pain relief. During the trial, temporary leads are placed and connected to an external generator, allowing patients to experience firsthand the impact of neuromodulation on their chronic pain and related symptoms.
NeuroSphere myPath will be compatible with Abbott’s Proclaim XR SCS System for patients living with chronic pain in the trunk and limbs, and Proclaim DRG Neurostimulation System for patients with chronic pain in the lower limbs caused by complex regional pain syndrome or causalgia, per the release.
The NeuroSphere myPath will be available on the Apple App Store in the coming weeks and is expected to be available on Android devices in Q2 2021.
[Source(s): Abbott, PR Newswire]
Related Content:
Virtual Reality Gives Spinal Cord Stimulation a Boost
Spinal Cord Stimulation and PT May Help Enable Supported Standing, Walking in Paralyzed Patients
Abbott Shares Study Data Suggesting Benefits of Proclaim XR for Chronic Pain
